{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:10:23Z","timestamp":1785409823475,"version":"3.56.0"},"reference-count":70,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natural Science Foundation of Jilin Provincial Department of Science and Technology","award":["YDZJ202501ZYTS573"],"award-info":[{"award-number":["YDZJ202501ZYTS573"]}]},{"DOI":"10.13039\/501100010211","name":"Department of Education of Jilin Province","doi-asserted-by":"publisher","award":["JJKH20250418KJ"],"award-info":[{"award-number":["JJKH20250418KJ"]}],"id":[{"id":"10.13039\/501100010211","id-type":"DOI","asserted-by":"publisher"}]},{"award":["JJKH20250418KJ"],"award-info":[{"award-number":["JJKH20250418KJ"]}],"id":[{"id":"https:\/\/ror.org\/05782e512","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Babesiosis is a zoonosis caused by protozoan parasites of the genus Babesia. It has a worldwide distribution and affects many kinds of mammals, principally domestic animals and humans. Because there are no safe and effective vaccines available, the treatment and control for babesiosis continues to involve the use of chemotherapeutics. For years, only a few drugs have been used for clinical treatment, namely atovaquone plus azithromycin or clindamycin plus quinine for human, and imidocarb dipropionate and diminazene aceturate for domestic animals. Although screening and developing alternative drugs are continuously pursued, only a few drugs have been prospected to have clinical applications. Of these, tafenoquine has shown wide and potent antibabesial activity, offering a new option to control babesiosis. This article aims to present the current clinical therapeutic strategies for babesiosis and their limitations, as well as the prospect of tafenoquine as a promising drug to treat babesiosis.<\/jats:p>","DOI":"10.3390\/tropicalmed11050141","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:55:28Z","timestamp":1779180928000},"page":"141","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tafenoquine: A Breakthrough Option for Babesiosis Treatment"],"prefix":"10.3390","volume":"11","author":[{"given":"Dongxue","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Veterinary Medicine, Agriculture College, Yanbian University, Yanji 133000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-1848","authenticated-orcid":false,"given":"Mo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Swine Infectious Diseases Division, Jiangsu Key Laboratory for High-Tech Research and Development of Veterinary Biopharmaceuticals, Engineering Technology Research Center for Modern Animal Science and Novel Veterinary Pharmaceutic Development, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225306, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-6553","authenticated-orcid":false,"given":"Shinuo","family":"Cao","sequence":"additional","affiliation":[{"name":"Swine Infectious Diseases Division, Jiangsu Key Laboratory for High-Tech Research and Development of Veterinary Biopharmaceuticals, Engineering Technology Research Center for Modern Animal Science and Novel Veterinary Pharmaceutic Development, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225306, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-8401","authenticated-orcid":false,"given":"Eloiza May","family":"Galon-Bedonia","sequence":"additional","affiliation":[{"name":"Department of Basic Veterinary Sciences, College of Veterinary Medicine and Biomedical Sciences, Cavite State University, Cavite 4122, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, Agriculture College, Yanbian University, Yanji 133000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, Agriculture College, Yanbian University, Yanji 133000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, Agriculture College, Yanbian University, Yanji 133000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujiang","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, Agriculture College, Yanbian University, Yanji 133000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-4809","authenticated-orcid":false,"given":"Shengwei","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, Agriculture College, Yanbian University, Yanji 133000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/CMR.13.3.451","article-title":"Babesiosis","volume":"13","author":"Homer","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.meegid.2012.07.004","article-title":"Babesia: A World Emerging","volume":"12","author":"Schnittger","year":"2012","journal-title":"Infect. Genet. Evol."},{"key":"ref_3","first-page":"11","article-title":"Piroplasmosis in man; report of a case","volume":"9","author":"Skrabalo","year":"1957","journal-title":"Doc. Med. Geogr. Trop."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e39960","DOI":"10.1016\/j.heliyon.2024.e39960","article-title":"Persistent human babesiosis with low-grade parasitemia, challenges for clinical diagnosis and management","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14787210.2020.1752193","article-title":"Management strategies for human babesiosis","volume":"18","author":"Smith","year":"2020","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5889219","DOI":"10.1155\/tbed\/5889219","article-title":"Mapping the Global Distribution of Babesia Infections","volume":"2025","author":"Fu","year":"2025","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/CMR.16.4.622-636.2003","article-title":"Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance","volume":"16","author":"Zintl","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.vetpar.2011.05.032","article-title":"Emerging perspectives in the research of bovine babesiosis and anaplasmosis","volume":"180","author":"Suarez","year":"2011","journal-title":"Vet. Parasitol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.vetpar.2005.07.002","article-title":"Cellular adhesive phenomena in apicomplexan parasites of red blood cells","volume":"132","author":"Cooke","year":"2005","journal-title":"Vet. Parasitol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1051\/vetres\/2009020","article-title":"Babesia and its hosts: Adaptation to long-lasting interactions as a way to achieve efficient transmission","volume":"40","author":"Chauvin","year":"2009","journal-title":"Vet. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.pt.2019.01.007","article-title":"Babesia Life Cycle\u2014When Phylogeny Meets Biology","volume":"35","author":"Jalovecka","year":"2019","journal-title":"Trends Parasitol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bloch, E.M., Krause, P.J., and Tonnetti, L. (2021). Preventing Transfusion-Transmitted Babesiosis. Pathogens, 10.","DOI":"10.3390\/pathogens10091176"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMra1202018","article-title":"Human Babesiosis","volume":"366","author":"Vannier","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.vetpar.2006.01.048","article-title":"Chemotherapy against babesiosis","volume":"138","author":"Vial","year":"2006","journal-title":"Vet. Parasitol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ttbdis.2009.11.003","article-title":"Zoonotic babesiosis: Overview of the disease and novel aspects of pathogen identity","volume":"1","author":"Gray","year":"2010","journal-title":"Ticks Tick-Borne Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e17172","DOI":"10.1016\/j.heliyon.2023.e17172","article-title":"Babesiosis: Current status and future perspectives in Pakistan and chemotherapy used in livestock and pet animals","volume":"9","author":"Azhar","year":"2023","journal-title":"Heliyon"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/ciab050","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis","volume":"72","author":"Krause","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/cid\/cix477","article-title":"Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed Babesia microti infection associated with rituximab and chronic lymphocytic leukemia","volume":"65","author":"Simon","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"16079","DOI":"10.1038\/nmicrobiol.2016.79","article-title":"A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse","volume":"1","author":"Lemieux","year":"2016","journal-title":"Nat. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Renard, I., and Ben Mamoun, C. (2021). Treatment of Human Babesiosis: Then and Now. Pathogens, 10.","DOI":"10.3390\/pathogens10091120"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.20151519","article-title":"Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone","volume":"213","author":"Lawres","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vetpar.2018.03.001","article-title":"Antiprotozoal treatment of canine babesiosis","volume":"254","author":"Baneth","year":"2018","journal-title":"Vet. Parasitol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-3024.2005.00748.x","article-title":"Possible mechanisms underlying age-related resistance to bovine babesiosis","volume":"27","author":"Zintl","year":"2005","journal-title":"Parasite Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0090-9556(25)06588-2","article-title":"Imidocarb residues in edible bovine tissues and in vitro assessment of imidocarb metabolism and cytotoxicity","volume":"23","author":"Coldham","year":"1995","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0378-4274(96)03705-8","article-title":"A cellular mechanism for imidocarb retention in edible bovine tissues","volume":"87","author":"Moore","year":"1996","journal-title":"Toxicol. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3168\/jds.S0022-0302(06)72320-7","article-title":"Pharmacokinetics and mammary elimination of imidocarb in sheep and goats","volume":"89","author":"Belloli","year":"2006","journal-title":"J. Dairy Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.intimp.2014.05.027","article-title":"Diminazene aceturate (Berenil), a new use for an old compound?","volume":"21","author":"Kuriakose","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2015.10.005","article-title":"Diminazene aceturate\u2014An antiparasitic drug of antiquity: Advances in pharmacology & therapeutics","volume":"102","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0034-5288(18)31941-6","article-title":"Chemoprophylaxis with diminazene aceturate in experimental Babesia bigemina infection in cattle","volume":"37","author":"Sharma","year":"1984","journal-title":"Res. Vet. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11250-007-9121-2","article-title":"Comparative efficacy of diminazene diaceturate and diminazene aceturate for the treatment of babesiosis in horses","volume":"40","author":"Rashid","year":"2008","journal-title":"Trop. Anim. Health Prod."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1292\/jvms.09-0535","article-title":"Development and characterization of a strain of Babesia gibsoni resistant to diminazene aceturate in vitro","volume":"72","author":"Hwang","year":"2010","journal-title":"J. Vet. Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1292\/jvms.12-0056","article-title":"Involvement of mitochondrial genes of Babesia gibsoni in resistance to diminazene aceturate","volume":"74","author":"Yamasaki","year":"2012","journal-title":"J. Vet. Med. Sci."},{"key":"ref_34","first-page":"51","article-title":"Analysis of energy generation and glycolysis pathway in diminazene aceturate-resistant Babesia gibsoni isolate in vitro","volume":"60","author":"Yamasaki","year":"2012","journal-title":"Jpn. J. Vet. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.pt.2008.02.006","article-title":"Molecular tools for the rapid detection of drug resistance in animal trypanosomes","volume":"24","author":"Delespaux","year":"2008","journal-title":"Trends Parasitol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijpddr.2019.02.001","article-title":"Development of unstable resistance to diminazene aceturate in Babesia bovis","volume":"9","author":"Tuvshintulga","year":"2019","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mayence, A., and Vanden Eynde, J.J. (2019). Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria. Pharmaceuticals, 12.","DOI":"10.3390\/ph12030115"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40265-018-0979-2","article-title":"Tafenoquine: First Global Approval","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"tay071","DOI":"10.1093\/jtm\/tay071","article-title":"Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax","volume":"25","author":"Tan","year":"2018","journal-title":"J. Travel Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1475-2875-10-351","article-title":"Primaquine in vivax malaria: An update and review on management issues","volume":"10","author":"Fernando","year":"2011","journal-title":"Malar. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/13543784.16.5.705","article-title":"Tafenoquine: A promising new antimalarial agent","volume":"16","author":"Crockett","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4269\/ajtmh.1998.58.645","article-title":"First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial","volume":"58","author":"Brueckner","year":"1998","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1179\/2047773215Y.0000000013","article-title":"Killing the hypnozoite\u2014Drug discovery approaches to prevent relapse in Plasmodium vivax","volume":"109","author":"Campo","year":"2015","journal-title":"Pathog. Glob. Health"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2147\/DDDT.S61443","article-title":"Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: The evidence to date","volume":"10","author":"Ebstie","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/14656566.2022.2058394","article-title":"Tafenoquine for the treatment of Plasmodium vivax malaria","volume":"23","author":"Manrrique","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/AAC.43.3.598","article-title":"8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization","volume":"43","author":"Vennerstrom","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4269\/ajtmh.1990.42.532","article-title":"In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei","volume":"42","author":"Bates","year":"1990","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/BF00928413","article-title":"Effect of the 8-aminoquinoline primaquine on culture-derived gametocytes of the malaria parasite Plasmodium falciparum","volume":"77","author":"Lanners","year":"1991","journal-title":"Parasitol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.00790-10","article-title":"Tafenoquine, an antiplasmodial 8-aminoquinoline, targets leishmania respiratory complex III and induces apoptosis","volume":"54","author":"Carvalho","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1128\/AAC.00879-15","article-title":"The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei","volume":"59","author":"Carvalho","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e0020421","DOI":"10.1128\/AAC.00204-21","article-title":"Tafenoquine Is a Promising Drug Candidate for the Treatment of Babesiosis","volume":"65","author":"Liu","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jiz119","article-title":"Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?","volume":"220","author":"Mordue","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.42.5.1293","article-title":"Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial","volume":"42","author":"Brueckner","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Birrell, G.W., Van Breda, K., Barber, B., Webster, R., McCarthy, J.S., Shanks, G.D., and Edstein, M.D. (2022). Quantification of Tafenoquine and 5,6-Orthoquinone Tafenoquine by UHPLC-MS\/MS in Blood, Plasma, and Urine, and Application to a Pharmacokinetic Study. Molecules, 27.","DOI":"10.3390\/molecules27238186"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(00)02352-7","article-title":"Malaria chemoprophylaxis with tafenoquine: A randomised study","volume":"355","author":"Lell","year":"2000","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1086\/424508","article-title":"Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse","volume":"39","author":"Walsh","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1086\/424468","article-title":"Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria","volume":"190","author":"Walsh","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1086\/324081","article-title":"A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria","volume":"33","author":"Shanks","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e00011-19","DOI":"10.1128\/CMR.00011-19","article-title":"8-Aminoquinoline Therapy for Latent Malaria","volume":"32","author":"Baird","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1128\/AAC.01588-16","article-title":"Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects","volume":"60","author":"Green","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMe1816383","article-title":"Tafenoquine\u2014A Radical Improvement?","volume":"380","author":"White","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1073\/pnas.83.12.4157","article-title":"Human glucose-6-phosphate dehydrogenase: Primary structure and cDNA cloning","volume":"83","author":"Takizawa","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1128\/AAC.41.1.91","article-title":"Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model","volume":"41","author":"Marley","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1292\/jvms.24-0443","article-title":"Efficacy of tafenoquine in dogs naturally infected with Babesia gibsoni","volume":"87","author":"Iguchi","year":"2025","journal-title":"J. Vet. Med. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e01460","DOI":"10.1016\/j.idcr.2022.e01460","article-title":"Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone","volume":"27","author":"Marcos","year":"2022","journal-title":"IDCases"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/cid\/ciac473","article-title":"Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine","volume":"76","author":"Rogers","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Prasad, P.J., and Wormser, G.P. (2022). Failure of an Approximately Six Week Course of Tafenoquine to Completely Eradicate Babesia microti Infection in an Immunocompromised Patient. Pathogens, 11.","DOI":"10.3390\/pathogens11091051"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/cid\/ciae238","article-title":"Tafenoquine for Relapsing Babesiosis: A Case Series","volume":"79","author":"Krause","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/infdis\/jiae083","article-title":"Tafenoquine-Based Combination Therapies: A Step Toward Babesiosis Elimination","volume":"229","author":"Liu","year":"2024","journal-title":"J. Infect. Dis."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/11\/5\/141\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:22:23Z","timestamp":1779272543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/11\/5\/141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":70,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["tropicalmed11050141"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed11050141","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}